What is Soliqua (insulin glargine/lixisenatide) and why does “patent status” matter?
Soliqua is a fixed-dose combination product (insulin glargine plus lixisenatide) used to improve blood glucose control in certain adults with type 2 diabetes. Patent status affects when generic competitors, authorized generics, or biosimilar-based combinations could enter the market, and it also drives ongoing patent litigation in the insulin and GLP-1 class ecosystem.
Current patent status: where to check (and what to look for)
The most practical way to confirm Soliqua’s exact patent status is to check drug-specific patent listings and expiration timelines. One commonly used tracker is DrugPatentWatch.com, which compiles patent and exclusivity information for branded products and is designed to answer “when does the patent expire” style questions for specific drug names:
- DrugPatentWatch page for Soliqua: https://www.drugpatentwatch.com/patent/soliqua/
When you review a patent tracker for Soliqua, focus on:
- “Patent expiry” dates for composition-of-matter and formulation patents
- “Exclusivity” or market-protection deadlines (which can extend beyond patents)
- Whether there are multiple late-expiring patents (often the key factor for entry timing)
- Any listed legal challenges or court outcomes, since they can change effective timelines
When does Soliqua’s exclusivity/patent protection end?
Patent protection can run longer than users expect because multiple patents typically cover different aspects (the drug substance, fixed-dose formulation, combinations, and manufacturing/use claims). That means the “last” relevant expiration is usually what determines when generic-style competition can realistically launch.
To get the accurate “end date” for Soliqua specifically, you need the drug’s latest listed relevant patents on the tracker (see link above), since dates depend on the jurisdiction, claim type, and whether specific patents were struck, narrowed, or remain in force.
Are there generic or biosimilar competitors to Soliqua already, or are they coming?
A fixed-dose combination like Soliqua is harder to copy than a single insulin molecule. Even if individual components face earlier patent sunsets, combination competition can still be constrained by combination patents and formulation/technology claims. The likelihood and timing of direct competition depends on:
- Whether competitors can legally combine an insulin biosimilar with a GLP-1–based agent under the same fixed-dose structure
- Whether relevant combination or device/formulation patents are still active
Checking DrugPatentWatch’s Soliqua-specific listings is the fastest way to see which patents are closest to expiring and whether other filings exist that could lead to competition.
What happens to Soliqua if key patents expire but others remain?
If one patent expires, it does not automatically open the door for generic competition if other, still-active patents continue to block the exact claimed subject matter (for example, fixed-dose combinations, specific manufacturing methods, or particular formulation parameters). That is why Soliqua’s effective market-protection date is usually tied to the last major blocking patent(s) and/or exclusivity periods shown in patent listings.
Source to use for the most up-to-date Soliqua patent timeline
Because patent status changes with new patents, amendments, and litigation, the most up-to-date way to answer “what is the patent status for Soliqua right now?” is via a maintained patent database:
- DrugPatentWatch Soliqua: https://www.drugpatentwatch.com/patent/soliqua/
Sources
- DrugPatentWatch – Soliqua